drugset / Trial / NCT00351065
Phase II Trial of SK3530 in Erectile Dysfunction
RandomizedParallel-groupDouble-blindTreatment
Summary
This study was designed to evaluate the efficacy and safety of the SK3530 tablet and to find the optimal dose and dosage schedule after oral administration to patients with erectile dysfunction.
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2005-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirodenafil | Small molecule | 50 mg | Oral |
| Subject | Mirodenafil | Small molecule | 100 mg | Oral |
| Subject | Mirodenafil | Small molecule | 150 mg | Oral |